Yesterday, a panel of Federal Judges ruled that 21 lawsuits against the drug manufacturer Boehringer Ingelheim Pharmaceuticals should be joined together in front of one Federal Judge in the Southern District of Illinois. This consolidation, known as multi-district litigation, is intended to allow cases to move along more quickly and efficiently. The cases that have been filed come from a variety of states including Florida, Illinois, Kentucky and Tennessee.
Pradaxa, which is also known by its scientific name Dabigatran, is a medication that is used to prevent strokes in patients with atrial fibrillation. The lawsuits that have been filed allege that Prodaxa also causes life threatening internal bleeding and has led to patients suffering gastro-intestinal bleeding requiring transfusions and other interventions and in some cases, causing death.
The Pradaxa cases have been consolidated in front of Federal Court Judge David Herndon who did an outstanding job handling the multi-district litigation regarding the Yasmin and Yaz. While there is a long way to go, those injured as a result of taking Pradaxa and loved ones of those who died as a result of the drug, are now one step closer to seeking closure.
The pharmaceutical industry has a responsibility to ensure the safety of the patients who are taking their drugs. If a drug that is supposed to improve a patient’s health actually endangers it, patients have the right to hold the pharmaceutical company responsible. Experienced Louisville dangerous drugs attorney, Tad Thomas is dedicated to helping injured victims of defective drugs obtain the compensation they need for recovery.